Issue 6/2018
Content (20 Articles)
Autophagy modulation: a prudent approach in cancer treatment?
Eleanor Bishop, Tracey D. Bradshaw
Autophagy therapeutics: preclinical basis and initial clinical studies
Lei Zhan, Jun Li, Bing Wei
Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)
Joan Maurel, Santiago Sánchez-Cabús, Berta Laquente, Lydia Gaba, Laura Visa, Joan Fabregat, Ignacio Povés, Susana Roselló, Roberto Díaz-Beveridge, Marta Martín-Richard, Javier Rodriguez, Luis Sabater, Carles Conill, María Cambray, Ana Reig, Juan Ramón Ayuso, Carlos Valls, Antonio Ferrández, Josep Antoni Bombí, Angels Ginés, Xabier García-Albéniz, Laureano Fernández-Cruz
Single agent efficacy of the HDAC inhibitor DATS in preclinical models of glioblastoma
Arabinda Das, Fraser Henderson Jr., Stephen Lowe, Gerald C. Wallace IV, William A. Vandergrift III, Scott M. Lindhorst, Abhay K. Varma, Libby K. Infinger, Pierre Giglio, Narendra L. Banik, Sunil J. Patel, David Cachia
The maximum chemiluminescence intensity predicts severe neutropenia in gemcitabine-treated patients with pancreatic or biliary tract cancer
Koki Goto, Ryusei Matsuyama, Yusuke Suwa, Sayaka Arisaka, Toshiaki Kadokura, Mari Sato, Ryutaro Mori, Takafumi Kumamoto, Masataka Taguri, Itaru Endo
Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer
Robert J. Mayer, Howard S. Hochster, Steven J. Cohen, Robert Winkler, Lukas Makris, Axel Grothey
Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
Seiichi Hayato, Robert Shumaker, Jim Ferry, Terri Binder, Corina E. Dutcus, Ziad Hussein
Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer
Nicolas Martin, Nicolas Isambert, Carlos Gomez-Roca, Rainer-Georg Goeldner, Sylvie Zanetta, Behbood Sadrolhefazi, Hélène de Mont-Serrat, Mario Campone, Jean-Pierre Delord
Relationship between folate concentration and expression of folate-associated genes in tissue and plasma after intraoperative administration of leucovorin in patients with colorectal cancer
Helena Taflin, Elisabeth Odin, Kristoffer Derwinger, Göran Carlsson, Bengt Gustavsson, Yvonne Wettergren
Lactobacillus supplementation prevents cisplatin-induced cardiotoxicity possibly by inflammation inhibition
Lianbi Zhao, Changyang Xing, Wenqi Sun, Guangli Hou, Guodong Yang, Lijun Yuan
Oleandrin synergizes with cisplatin in human osteosarcoma cells by enhancing cell apoptosis through activation of the p38 MAPK signaling pathway
Lei Yong, Yunlong Ma, Bin Zhu, Xiao Liu, Peng Wang, Chen Liang, Guanping He, Zhigang Zhao, Zhongjun Liu, Xiaoguang Liu
A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients
Tetsuya Hamaguchi, Akihito Tsuji, Kensei Yamaguchi, Koji Takeda, Hiroyuki Uetake, Taito Esaki, Kenji Amagai, Daisuke Sakai, Hideo Baba, Masami Kimura, Yasuhiro Matsumura, Tetsuji Tsukamoto
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403
Naohiro Oda, Kastuyuki Hotta, Kiichiro Ninomiya, Daisuke Minami, Eiki Ichihara, Toshi Murakami, Toshihide Yokoyama, Hirohisa Ichikawa, Kenichi Chikamori, Nagio Takigawa, Nobuaki Ochi, Shingo Harita, Yoshinobu Maeda, Katsuyuki Kiura
Oncogenic roles of serine–threonine kinase receptor-associated protein (STRAP) in osteosarcoma
Dumnoensun Pruksakorn, Jeerawan Klangjorhor, Kriengsak Lirdprapamongkol, Pimpisa Teeyakasem, Patsadakorn Sungngam, Parunya Chaiyawat, Areerak Phanphaisarn, Jongkolnee Settakorn, Chantragan Srisomsap
FOXC2 promotes epithelial–mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells
Yuwen He, Hui Xie, Pengjiu Yu, Shunjun Jiang, Li Wei
No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer
Takeo Kosaka, Hiroshi Hongo, Keitaro Watanabe, Ryuichi Mizuno, Eiji Kikuchi, Mototsugu Oya
Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer
Tomas Vilimas, Amy Q. Wang, Samarjit Patnaik, Emma A. Hughes, Marc D. Singleton, Zachary Knotts, Dandan Li, Kevin Frankowski, Jerome J. Schlomer, Theresa M. Guerin, Stephanie Springer, Catherine Drennan, Christopher Dextras, Chen Wang, Debra Gilbert, Noel Southall, Marc Ferrer, Sui Huang, Serguei Kozlov, Juan Marugan, Xin Xu, Udo Rudloff
Enhancing 5-fluorouracil efficacy through suppression of PKM2 in colorectal cancer cells
Yong Cao, Yan Lin, Dongxu Wang, Di Pan, Ying Zhang, Yu Jin, Changqing Zheng
Comment on: Yohshino et al.: combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer Chemother Pharmacol (2017) 80:1239–1247
Michael Eichbaum, Christine Eichbaum